Condition: Post-Acute COVID-19 Syndrome · Sponsor: Resverlogix Corp
This is an open label, multicentre, phase II clinical trial that aims to assess the efficacy and safety of oral Apabetalone with background dapagliflozin for up to 12 weeks in T2DM patients with a history of probable or confirmed SARS-CoV-2 infection, with symptoms within 3 months from the onset of COVID-19 that last for at least 2 months and cannot be explained by an alternative diagnosis.
This description comes directly from the study's public registry record.
Omar Hamed · (+971)429704901 · Omar.Hamed@pdc-cro.com
Moaz Rashad · (+971)581154600 · moaz.rashad@pdc-cro.com
Always discuss trial participation with your own doctor first.
| The Speciality Hospital | Amman, Jordan | Not Yet Recruiting |
| MNGHA- King Abdulaziz Hospital | Al Mubarraz, Saudi Arabia | Not Yet Recruiting |
| Al Kuwait Hospital | Dubai, Dubai, United Arab Emirates | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06590324